CL2007000797A1 - Pharmaceutical composition comprising between about 1 and 150 mg / ml of humab igf-1r, between about 0.001 and 1% of at least one humectant, between about 1 and 100 mm of a cap at a ph between about 5 and 7; and use for the treatment of breast cancer, lung cancer and prostate cancer - Google Patents
Pharmaceutical composition comprising between about 1 and 150 mg / ml of humab igf-1r, between about 0.001 and 1% of at least one humectant, between about 1 and 100 mm of a cap at a ph between about 5 and 7; and use for the treatment of breast cancer, lung cancer and prostate cancerInfo
- Publication number
- CL2007000797A1 CL2007000797A1 CL2007000797A CL2007000797A CL2007000797A1 CL 2007000797 A1 CL2007000797 A1 CL 2007000797A1 CL 2007000797 A CL2007000797 A CL 2007000797A CL 2007000797 A CL2007000797 A CL 2007000797A CL 2007000797 A1 CL2007000797 A1 CL 2007000797A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer
- treatment
- pharmaceutical composition
- humectant
- cap
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Composición farmacéutica que comprende entre alrededor de 1y 150 mg/ml de humab igf-1r, entre alrededor de 0,001 y 1% de al menos un surfactante, entre alrededor de 1 y 100 mm de un tampón a un Ph entre alrededor de 5 y 7; y uso para el tratamiento de cáncer de mama, cáncer colorectal, cáncer de pulmón y de próstata.Pharmaceutical composition comprising between about 1 and 150 mg / ml of humab igf-1r, between about 0.001 and 1% of at least one surfactant, between about 1 and 100 mm of a buffer at a Ph between about 5 and 7 ; and use for the treatment of breast cancer, colorectal cancer, lung and prostate cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06111848 | 2006-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007000797A1 true CL2007000797A1 (en) | 2008-01-25 |
Family
ID=37025222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2007000797A CL2007000797A1 (en) | 2006-03-28 | 2007-03-26 | Pharmaceutical composition comprising between about 1 and 150 mg / ml of humab igf-1r, between about 0.001 and 1% of at least one humectant, between about 1 and 100 mm of a cap at a ph between about 5 and 7; and use for the treatment of breast cancer, lung cancer and prostate cancer |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1998806A1 (en) |
JP (1) | JP2009531371A (en) |
KR (1) | KR20080104160A (en) |
CN (1) | CN101410137A (en) |
AR (1) | AR060130A1 (en) |
AU (1) | AU2007229554A1 (en) |
BR (1) | BRPI0709229A2 (en) |
CA (1) | CA2647111A1 (en) |
CL (1) | CL2007000797A1 (en) |
CR (1) | CR10295A (en) |
EC (1) | ECSP088778A (en) |
IL (1) | IL193904A0 (en) |
MA (1) | MA30345B1 (en) |
MX (1) | MX2008012295A (en) |
NO (1) | NO20083895L (en) |
RU (1) | RU2008142359A (en) |
TW (1) | TW200815029A (en) |
WO (1) | WO2007110339A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9968676B2 (en) | 2009-07-31 | 2018-05-15 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009006199A (en) * | 2006-12-11 | 2009-06-22 | Hoffmann La Roche | Abeta antibody parenteral formulation. |
GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
US20100260766A1 (en) * | 2007-03-22 | 2010-10-14 | Arvind Srivastava | Stable antibody formulations |
CN101687038A (en) * | 2007-07-10 | 2010-03-31 | 霍夫曼-拉罗奇有限公司 | Novel formulation |
JP5205470B2 (en) * | 2007-11-29 | 2013-06-05 | エフ.ホフマン−ラ ロシュ アーゲー | Immunoglobulin aggregates |
AU2008340429C1 (en) * | 2007-12-21 | 2016-09-08 | F. Hoffmann-La Roche Ag | Antibody formulation |
WO2010069858A1 (en) * | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
AR078161A1 (en) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD |
MX2012007676A (en) * | 2009-12-29 | 2012-08-03 | Hoffmann La Roche | Antibody formulation. |
WO2011147921A1 (en) * | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
KR102031020B1 (en) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
CN102363040B (en) * | 2011-10-21 | 2013-05-01 | 北京锐瑟科技有限公司 | Antimicrobial peptide preparation for mucosal tissues |
JP2016528167A (en) | 2013-04-29 | 2016-09-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Human FcRn binding modified antibody and method of use |
CN103505729B (en) * | 2013-05-24 | 2015-10-28 | 华北制药集团新药研究开发有限责任公司 | A kind of stable rabies virus human antibody combination preparation |
CN104707146B (en) * | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | A kind of pharmaceutical composition containing adalimumab |
BR112016014969A2 (en) | 2014-01-15 | 2018-01-23 | Hoffmann La Roche | polypeptide, pharmaceutical formulation and use of a polypeptide |
US10206878B2 (en) * | 2014-05-28 | 2019-02-19 | Nono Inc. | Lyophilized formulation of TAT-NR2B9C with acetylation scavenger |
AR102198A1 (en) | 2014-10-09 | 2017-02-08 | Regeneron Pharma | PROCESS TO REDUCE SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION |
PE20221007A1 (en) | 2015-06-24 | 2022-06-15 | Hoffmann La Roche | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH ENGINEERED AFFINITY |
CN106999591B (en) * | 2015-09-28 | 2021-02-23 | 苏州盛迪亚生物医药有限公司 | anti-PD-1 antibody preparation and application thereof in medicine |
CN114031689A (en) | 2015-10-02 | 2022-02-11 | 豪夫迈·罗氏有限公司 | Bispecific anti-human CD 20/human transferrin receptor antibodies and methods of use |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
CN106199007B (en) * | 2016-08-03 | 2017-04-05 | 烟台普罗吉生物科技发展有限公司 | Protein protective agent |
EP3500297A1 (en) | 2016-08-16 | 2019-06-26 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
PL3532838T3 (en) | 2016-10-25 | 2022-10-03 | Regeneron Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
RU2019138507A (en) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | ANTIBODY AGAINST LAG3 AND JOINT ANTIBODY AGAINST LAG3 AND ANTIBODY AGAINST PD-1 |
JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
TW202005694A (en) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | Systems and methods for preparing a polypeptide from a mixture |
CN114324882B (en) * | 2020-10-12 | 2022-12-27 | 广东菲鹏生物有限公司 | Protein stabilizer and application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3919235B2 (en) * | 1997-06-13 | 2007-05-23 | ジェネンテク,インコーポレイテッド | Antibody preparation |
PT1399483E (en) * | 2001-01-05 | 2010-07-20 | Pfizer | Antibodies to insulin-like growth factor i receptor |
JP4317010B2 (en) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | Stable lyophilized pharmaceutical formulation of IgG antibody |
ES2383014T3 (en) * | 2003-04-02 | 2012-06-15 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor I and their uses |
SI2335725T1 (en) * | 2003-04-04 | 2017-01-31 | Genentech, Inc. | High concentration antibody and protein formulations |
AR046071A1 (en) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME |
PL1656391T3 (en) * | 2003-08-13 | 2011-03-31 | Pfizer Prod Inc | Modified human igf-1r antibodies |
-
2007
- 2007-03-19 AU AU2007229554A patent/AU2007229554A1/en not_active Abandoned
- 2007-03-19 EP EP07727047A patent/EP1998806A1/en not_active Withdrawn
- 2007-03-19 BR BRPI0709229-6A patent/BRPI0709229A2/en not_active IP Right Cessation
- 2007-03-19 CA CA002647111A patent/CA2647111A1/en not_active Abandoned
- 2007-03-19 KR KR1020087023673A patent/KR20080104160A/en not_active Application Discontinuation
- 2007-03-19 CN CNA2007800114320A patent/CN101410137A/en active Pending
- 2007-03-19 MX MX2008012295A patent/MX2008012295A/en active IP Right Grant
- 2007-03-19 WO PCT/EP2007/052569 patent/WO2007110339A1/en active Application Filing
- 2007-03-19 JP JP2009502016A patent/JP2009531371A/en active Pending
- 2007-03-19 RU RU2008142359/15A patent/RU2008142359A/en not_active Application Discontinuation
- 2007-03-26 CL CL2007000797A patent/CL2007000797A1/en unknown
- 2007-03-26 AR ARP070101241A patent/AR060130A1/en not_active Application Discontinuation
- 2007-03-26 TW TW096110388A patent/TW200815029A/en unknown
-
2008
- 2008-09-04 IL IL193904A patent/IL193904A0/en unknown
- 2008-09-11 NO NO20083895A patent/NO20083895L/en not_active Application Discontinuation
- 2008-09-17 CR CR10295A patent/CR10295A/en not_active Application Discontinuation
- 2008-09-26 EC EC2008008778A patent/ECSP088778A/en unknown
- 2008-10-20 MA MA31308A patent/MA30345B1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9968676B2 (en) | 2009-07-31 | 2018-05-15 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2007110339A1 (en) | 2007-10-04 |
CN101410137A (en) | 2009-04-15 |
JP2009531371A (en) | 2009-09-03 |
TW200815029A (en) | 2008-04-01 |
KR20080104160A (en) | 2008-12-01 |
RU2008142359A (en) | 2010-05-10 |
MA30345B1 (en) | 2009-04-01 |
AU2007229554A1 (en) | 2007-10-04 |
IL193904A0 (en) | 2011-08-01 |
EP1998806A1 (en) | 2008-12-10 |
ECSP088778A (en) | 2008-10-31 |
CA2647111A1 (en) | 2007-10-04 |
AR060130A1 (en) | 2008-05-28 |
NO20083895L (en) | 2008-10-24 |
BRPI0709229A2 (en) | 2011-06-28 |
CR10295A (en) | 2008-10-06 |
MX2008012295A (en) | 2008-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007000797A1 (en) | Pharmaceutical composition comprising between about 1 and 150 mg / ml of humab igf-1r, between about 0.001 and 1% of at least one humectant, between about 1 and 100 mm of a cap at a ph between about 5 and 7; and use for the treatment of breast cancer, lung cancer and prostate cancer | |
AR069788A1 (en) | FORMULATION OF HUMAN ANTI-CD20 ANTIBODY AND USES OF THE SAME | |
CL2007002994A1 (en) | HETEROCICLIC DERIVATIVE COMPOUNDS CONTAINING SULFAMOIL, INHIBITORS OF HSP90; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER, SUCH AS CANCER OF BREAST, COLON AND PROSTATE, BETWEEN OTHERS. | |
CL2009000721A1 (en) | Combination comprising an isolated anti-igf1r antibody or an antigen-binding fragment thereof in association with leucovorin and 5-fluorouracil, leucovorin or sunitinib optionally associated with another chemotherapeutic agent; and its use for the treatment or prevention of colorectal cancer. | |
WO2007126457A3 (en) | Method and composition for treating and preventing tumor metastasis in vivo | |
CL2007002167A1 (en) | Indole derived compounds, iap antagonists; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer. | |
CR8181A (en) | USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER | |
SG164368A1 (en) | Treatment of cancer | |
UA100852C2 (en) | Composition for use in treating cancer | |
MY150697A (en) | Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha | |
CO6290650A2 (en) | BREAST CANCER TREATMENT WITH A PARP INHIBITOR ONLY OR IN COMBINATION WITH ANTI-TUMOR AGENTS | |
CL2008001656A1 (en) | Anti-c3b antibody; pharmaceutical composition comprising it, and its use to prevent or treat a complement-associated disorder; kit containing it. | |
CO6290649A2 (en) | PARP INHIBITOR 4-IODO-3-NITROBENZAMIDE OR A METABOLITE OF THE SAME AND AT LEAST AN ANTI-TUMORAL AGENT. | |
MX2010002247A (en) | Use of a combination of hesperidin and of a microorganism for influencing the barrier function of the skin. | |
ECSP088423A (en) | ANTINEOPLASIC COMBINATIONS WITH RAPAMYCIN OBJECTIVE INHIBITOR IN MAMMALS, HERCEPTINE, AND / OR HKI-272 | |
NO20080442L (en) | Phosphoramidate alkylator promoter | |
UY27943A1 (en) | COMPOSITIONS AND METHODS TO TREAT CRNCER USING ANTIBODY IMMUNOCATE PLAYS FOR CD44 CYTOTNXICS AND CHEMOTHERAPCUTIC AGENTS | |
MY145058A (en) | Prlr-specific antibody and uses thereof | |
MX2009005058A (en) | Methods of treating, diagnosing or detecting cancer. | |
WO2007053284A3 (en) | Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor | |
TNSN08401A1 (en) | Methods of treating diagnosing or detecting cancer | |
BRPI0511475A (en) | combination, pharmaceutical composition, use of a combination, and method for treating cancer | |
CR10996A (en) | CANCER TREATMENT METHOD THROUGH HUMAN IL-18 COMBINATION ADMINISTRATION | |
MX2009011822A (en) | Hydroxy sulfonate of quinone compounds and their uses. | |
WO2006086772A3 (en) | DIAGNOSING AND TREATING CANCER USING β-CATENIN SPLICE VARIANTS |